News

Targeted Oncology14d
Nivolumab Plus Ipilimumab Trends Toward Prolonged OS in nccRCC
Nivolumab plus ipilimumab showed a strong median overall survival (OS) advantage at 12 months and a trend toward overall prolonged OS vs SOC in non-clear cell renal cell carcinoma. The ...
Medscape15d
FDA OKs First-line Nivolumab + Ipilimumab in Advanced HCC
The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) as a first-line treatment for adults with ...
The American Journal of Managed Care18d
Nivolumab With Ipilimumab Approved by FDA for Use in Hepatocellular Carcinoma
The FDA approved nivolumab and ipilimumab for unresectable or metastatic hepatocellular carcinoma, a prevalent and deadly liver cancer in the U.S. CHECKMATE-9DW trial results showed improved ...
oncnursingnews18d
FDA Approves Nivolumab/Ipilimumab for Metastatic or Unresectable HCC
The FDA announced its approval of frontline nivolumab (Opdivo) plus ipilimumab (Yervoy) for use in adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), according to an ...
Targeted Oncology18d
FDA Approves Nivolumab/Ipilimumab in First-Line Hepatocellular Cancer
The FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). This regulatory decision is ...
Medscape20d
FDA Approves Nivolumab + Ipilimumab for Certain Patients With CRC
The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for the treatment of adults and children aged 12 ...
contemporarypediatrics20d
FDA approves nivolumab with ipilimumab for MSI-H, dMMR colorectal cancer
The federal agency greenlit nivolumab with ipilimumab for treating MSI-H/dMMR colorectal cancer in adults and children 12 years and up. On April 8, 2025, the FDA approved the combination of nivolumab ...
Cancer Therapy Advisor20d
Opdivo + Yervoy Approved as First-Line Tx for MSI-H/dMMR Metastatic Colorectal Cancer
The approval was supported by data from the CHECKMATE-8HW trial. The US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) as first-line ...
Seeking Alpha21d
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High ...
8 OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic ...
Business Insider21d
FDA approves nivolumab with ipilimumab for additional indication
The Food and Drug Administration announced it has approved nivolumab, or Opdivo, marketed by Bristol Myers (BMY) Squibb, with ipilimumab, or Yervoy, marketed by Bristol Myers, for adult and ...
The American Journal of Managed Care21d
Nivolumab Plus Ipilimumab FDA Approved for MSI-H, dMMR Colorectal Cancer
Nivolumab and ipilimumab combination approved for microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC), showing significant progression ...
Monthly Prescribing Reference21d
Opdivo + Yervoy Approved as First-Line Tx for MSI-H/dMMR Metastatic Colorectal Cancer
The risk of disease progression or death was reduced by 79% with nivolumab/ipilimumab compared with chemotherapy. The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab ...